UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 343

Sortiert nach

Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs

Current medicinal chemistry, 2015-01, Vol.22 (4), p.438

Kalgutkar, A S

2015

Volltextzugriff (PDF)

Transporter‐Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast

Clinical pharmacology and therapeutics, 2017-03, Vol.101 (3), p.406-415

2017

Volltextzugriff (PDF)

Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors

Journal of medicinal chemistry, 2000-07, Vol.43 (15), p.2860-2870

2000

Volltextzugriff (PDF)

Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors

Chemical research in toxicology, 2001-09, Vol.14 (9), p.1139-1162

2001

Volltextzugriff (PDF)

Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2

Science (American Association for the Advancement of Science), 1998-05, Vol.280 (5367), p.1268-1270

1998

Volltextzugriff (PDF)

A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385

The Journal of biological chemistry, 2003-11, Vol.278 (46), p.45763-45769

2003

Volltextzugriff (PDF)

A Semiquantitative Method for the Determination of Reactive Metabolite Conjugate Levels in Vitro Utilizing Liquid Chromatography−Tandem Mass Spectrometry and Novel Quaternary Ammonium Glutathione Analogues

Chemical research in toxicology, 2006-03, Vol.19 (3), p.480-490

2006

Volltextzugriff (PDF)

Cyclooxygenase 2 inhibitors: discovery, selectivity and the future

Trends in Pharmacological Sciences, 1999-11, Vol.20 (11), p.465-469

1999

Volltextzugriff (PDF)

A comprehensive listing of bioactivation pathways of organic functional groups

Current drug metabolism, 2005-06, Vol.6 (3), p.161

2005

Volltextzugriff (PDF)

Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor

Xenobiotica, 2010-06, Vol.40 (6), p.369-380

2010

Volltextzugriff (PDF)

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

The Journal of biological chemistry, 1999-08, Vol.274 (33), p.22903

1999

Volltextzugriff (PDF)

Biochemically Based Design of Cyclooxygenase-2 (COX-2) Inhibitors: Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective COX-2 Inhibitors

Proceedings of the National Academy of Sciences - PNAS, 2000-01, Vol.97 (2), p.925-930

2000

Volltextzugriff (PDF)

Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-Acetoxyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators

Journal of medicinal chemistry, 1998-11, Vol.41 (24), p.4800-4818

1998

Volltextzugriff (PDF)

Utility of multivariate analysis in support of in vitro metabolite identification studies: retrospective analysis using the antidepressant drug nefazodone

Xenobiotica, 2010-04, Vol.40 (4), p.262-274

2010

Volltextzugriff (PDF)

Reactive Drug Metabolites

1, 2012

Volltextzugriff (PDF)

Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents

Current drug targets, 2001-03, Vol.2 (1), p.79

2001

Volltextzugriff (PDF)

Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates

Annual review of pharmacology and toxicology, 2015-01, Vol.55 (1), p.35-54

2015

Volltextzugriff (PDF)

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

Drug metabolism and disposition, 2003-03, Vol.31 (3), p.243

2003

Volltextzugriff (PDF)

Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor α agonist in preclinical species and human

Xenobiotica, 2009-10, Vol.39 (10), p.766-781

2009

Volltextzugriff (PDF)

On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics

Current drug metabolism, 2002-08, Vol.3 (4), p.379

2002

Volltextzugriff (PDF)

Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents

Current opinion in chemical biology, 1998-08, Vol.2 (4), p.482-490

1998

Volltextzugriff (PDF)

Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

Xenobiotica, 2004-08, Vol.34 (8), p.755-770

2004

Volltextzugriff (PDF)

Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans

Drug metabolism and disposition, 2016-02, Vol.44 (2), p.209-219

2016

Volltextzugriff (PDF)

Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism

Medicinal research reviews, 1995-07, Vol.15 (4), p.325-388

1995

Volltextzugriff (PDF)

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

Drug metabolism and disposition, 2016-05, Vol.44 (5), p.692-699

2016

Volltextzugriff (PDF)

1 – 25 von 343

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(272)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Japanisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs

Transporter‐Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast

Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors

Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors

Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2

A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385

A Semiquantitative Method for the Determination of Reactive Metabolite Conjugate Levels in Vitro Utilizing Liquid Chromatography−Tandem Mass Spectrometry and Novel Quaternary Ammonium Glutathione Analogues

Cyclooxygenase 2 inhibitors: discovery, selectivity and the future

A comprehensive listing of bioactivation pathways of organic functional groups

Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

Biochemically Based Design of Cyclooxygenase-2 (COX-2) Inhibitors: Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective COX-2 Inhibitors

Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-Acetoxyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators

Utility of multivariate analysis in support of in vitro metabolite identification studies: retrospective analysis using the antidepressant drug nefazodone

Reactive Drug Metabolites

Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents

Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor α agonist in preclinical species and human

On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics

Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents

Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans

Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

Aktive Filter

Suchergebnisse filtern